Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with metastatic breast cancer: A systematic review and network meta-analysis

被引：0
|
作者：
Liu, Yi-Shao [1 ]
Dong, Kevin [1 ]
Park, Chanhyun [2 ]
机构：
[1] Univ Texas Austin, Austin, TX USA
[2] Univ Texas Austin, Coll Pharm, Hlth Outcomes Div, Austin, TX USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1218
引用
收藏
页码：575 / 576
页数：2
相关论文
共 50 条
  • [21] Inhibition of Cyclin-Dependent Kinases 4 and 6 in Breast Cancer
    Mayer, Erica L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (04) : 215 - 217
  • [22] Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
    Husinka, Lakyn
    Koerner, Pamela H.
    Miller, Rick T.
    Trombatt, William
    JOURNAL OF DRUG ASSESSMENT, 2021, 10 (01) : 27 - 34
  • [23] Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis
    Takatsuka, Daiki
    Sawaki, Masataka
    Hattori, Masaya
    Yoshimura, Akiyo
    Kotani, Haruru
    Kataoka, Ayumi
    Horisawa, Nanae
    Ozaki, Yuri
    Endo, Yuka
    Nozawa, Kazuki
    Iwata, Hiroji
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (05) : E175 - E182
  • [24] Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on CirculatingCells in Patients with Metastatic Breast Cancer
    Lobo-Martins, Soraia
    Corredeira, Patricia
    Cavaco, Ana
    Rodrigues, Carolina
    Piairo, Paulina
    Lopes, Claudia
    Fraga, Joana
    Silva, Madalena
    Alves, Patricia
    Szeneszi, Lisiana Wachholz
    Barradas, Ana
    Duran, Camila Castro
    Antunes, Marilia
    Nogueira-Costa, Goncalo
    Sousa, Rita
    Pinto, Conceicao
    Ribeiro, Leonor
    Abreu, Catarina
    Torres, Sofia
    Quintela, Antonio
    Mata, Gadea
    Megias, Diego
    Ribot, Julie
    Serre, Karine
    Casimiro, Sandra
    Silva-Santos, Bruno
    Dieguez, Lorena
    Costa, Luis
    CELLS, 2024, 13 (16)
  • [25] Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer
    Ratosa, Ivica
    Orazem, Miha
    Scoccimarro, Erika
    Steinacher, Mateja
    Dominici, Luca
    Aquilano, Michele
    Cerbai, Cecilia
    Desideri, Isacco
    Ribnikar, Domen
    Marinko, Tanja
    Livi, Lorenzo
    Meattini, Icro
    CLINICAL BREAST CANCER, 2020, 20 (06) : 495 - 502
  • [26] Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis
    Long, Quanyi
    Li, Xiaomin
    Wu, Gonghua
    Zhang, Jia
    Li, Hongjiang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (06) : 6556 - 6563
  • [27] The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)
    Eiger, Daniel
    Wagner, Marcio
    Ponde, Noam F.
    Nogueira, Melanie S.
    Buisseret, Laurence
    de Azambuja, Evandro
    ACTA ONCOLOGICA, 2020, 59 (06) : 723 - 725
  • [28] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
    Micha, John P.
    Rettenmaier, Mark A.
    Bohart, Randy D.
    Goldstein, Bram H.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 547 - 551
  • [29] Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
    Wang, Bin
    Li, Rui
    Wu, Shuai
    Liu, Xin
    Ren, Jianlin
    Li, Jing
    Bi, Kaixin
    Wang, Yanhong
    Jia, Hongyan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer
    Nina, Privsek
    Cvetka, Grasic Kuhar
    ONKOLOGIJA, 2021, 25 (02) : 48 - 53
12345